- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
Genomic Testing Cooperative provides research and pharma partners with advanced molecular testing services, AI-supported analysis tools, and scientific support for oncology research projects and clinical trials. Our DNA and RNA sequencing assays can be tailored to specific study requirements and expanded as projects evolve.
GTC supports retrospective studies, prospective clinical trials, biomarker discovery, companion diagnostic development, and customized assay design across solid tumors, hematologic malignancies, liquid biopsy, molecular and traditional IHC assays, and AI-driven interpretation workflows. Our cooperative model also provides access to a broader network of laboratories and institutions that can support multi-site testing, trial enrollment, and assay transfer when needed.
GTC supports research projects in solid tumors, hematologic malignancies, immuno-oncology, liquid biopsy, and molecular profiling. Our laboratory capabilities include DNA sequencing, RNA analysis, next-generation sequencing, Sanger sequencing, IHC support, bioinformatics, and customized assay development.
For clinical trials, GTC can support both retrospective and prospective study designs. Our team can help analyze archived samples, generate molecular data from new samples, support patient stratification, and provide testing workflows that align with trial-specific requirements.
GTC’s integrated DNA and RNA testing approach can help identify genomic alterations, expression patterns, fusion events, alternative splicing, immune-related features, and other biomarkers relevant to therapy response, resistance, classification, and clinical trial development.
GTC offers AI-supported and deep learning-based tools that can assist with biomarker cutoffs, responder and non-responder analysis, data interpretation, and customized research algorithms. Bioinformatics support can be included, or raw data files can be provided for analysis with a partner’s own tools.
GTC can help research and pharma partners analyze molecular data from past trials to gain deeper insight into tumor biology, therapeutic response, resistance patterns, and biomarker performance. Liquid biopsy can also be used to help categorize mutations from responders and non-responders, and GTC’s testing capabilities can support comparison with other companion diagnostic methodologies.
For prospective studies, GTC can support high-quality molecular data generation across tumor types using DNA and RNA analysis. Testing may include liquid biopsy for monitoring response to treatment, immune profiling, and multiple testing modalities such as FISH, IHC, flow cytometry, and cytogenetics when required by the study design.
GTC’s validated assays and cooperative laboratory network can support companion diagnostic development, including projects that may require multi-site testing, assay transfer, and preparation for regulatory pathways such as the 510(k) process.
GTC’s cooperative network can support research and pharma partners by providing access to multiple potential testing sites, trial enrollment sites, and collaborating institutions. Assays may also be transferred to qualified laboratories to support trial needs in different regions or countries.
This model allows partners to leverage broader institutional experience, shared testing perspectives, and scalable implementation pathways while maintaining scientific and operational alignment across the project.
GTC brings together advanced molecular testing, clinical laboratory expertise, data science, and a cooperative network designed to support scalable research and pharma programs.
Key advantages include:
Liquid Trace® supports liquid biopsy applications for both solid tumors and hematologic malignancies. The assay includes broad DNA and RNA coverage, fusion detection, biomarker analysis, and viral DNA testing for applications such as HPV and EBV where relevant to the study design.
Solid Tumor Profile Plus™ supports comprehensive molecular profiling of solid tumors using DNA and RNA analysis. The assay can support biomarker discovery, fusion detection, gene expression, alternative splicing, exon skipping, immune profiling, therapeutic insight, and clinical trial matching.
Hematology Profile Plus™ supports molecular profiling of hematologic malignancies, including leukemia, lymphoma, myeloma, MDS, CMML, AML, MPN, VEXAS-related investigation, and related research applications. The assay integrates DNA and RNA analysis to support classification, prognosis, therapeutic interpretation, and trial matching.
GTC can support IHC-related research workflows, including custom IHC, histology, and image analysis. Through collaborations, additional testing modalities such as flow cytometry, FISH, and cytogenetics may also be incorporated when required by the project.
GTC can collaborate with research and pharma partners to develop customized assay approaches for oncology and immuno-oncology projects. Study support can include custom panel development, sequencing strategy, bioinformatics support, AI analysis, raw data delivery, and integration of multiple testing modalities.
